Chong Kun Dang-Novartis deal biggest for Korea in five years

The two South Korea-based biotechs that licensed innovative assets to pharmas this week took the number one and two spots for largest upfront payments in such deals in the past five years.

BioCentury identified eight deals with disclosed financial terms since the start of 2019 that involved a South Korean biotech out-licensing an innovative technology or asset to a Western pharma company. The analysis excluded terminated deals and those involving biosimilars or manufacturing...